Imaging Mass Cytometry furthers important immune response investigations
Recent and rapid advancements in the field of immuno-oncology have bolstered our understanding of immune responses and accelerated immuno-oncology research. Leading researchers apply key tools and technology, including Imaging Mass Cytometry™, to better understand how the immune system responds towards cancer and potential immunotherapy treatments and to further biomarker discovery and development. Today, high-multiplex imaging to investigate the spatial biology of the complex tumor microenvironment (TME) plays a clear role in furthering these immuno-oncology studies.
Gaining an accurate understanding heterogeniety and phenotypes in the TME
The Hyperion™ Imaging System is a high-multiplex single-cell imaging solution that has proven use in characterizing the immune repertoire in the TME. Nearly 40% of the over 100 peer-reviewed publications using the Hyperion Imaging System have been in translational or clinical research focused on cancer and immuno-oncology. Many of these describe the TME and highlighting the role in immune and therapeutic responses.
Watch Bortolomeazzi and Montorsi present findings at the 2021 IMC Summit from Immunogenomics of colorectal cancer response to checkpoint blockade: Analysis of the KEYNOTE 177 trial and validation cohorts (link to IMC Summit recording).
Immuno-oncology Panel Kits for Imaging Mass Cytometry
Maxpar® panel kits for detection of human tumor-infiltrating lymphocytes, immune activation, and tissue architecture provide researchers with a richer, more insightful understanding of the cancer-related processes in the tumor microenvironment.
Insights into how IMC could impact prognosis in the future
The conclusion from Xie et al publication Hyperion Image Analysis Depicts a Preliminary Landscape of Tumor Immune Microenvironment in OSCC with Lymph Node Metastasis states “The Hyperion imaging system helped to delineate a preliminary and multidimensional landscape of the tumor immune microenvironment in OSCC with lymph node metastasis and provided insights into the influence of the immune microenvironment in determination of prognoses. These results reveal possible contributory factors behind different prognoses of OSCC patients with lymph node metastasis and provide reference for individual treatment planning.”
A new strategy could quell colorectal cancer metastasis to the liver
In the 2021 Cancer Cell publication “Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver,” Bertocchi et al. show that the PV-1 marker correlates with bacteria translocation and liver metastases and appears to serve as a prognostic marker for colorectal cancer distant recurrence and vascular impairment. This work offers insights to a new potential strategy to target tumor-associated bacteria to counteract liver metastases.
Learn about the multi-collaborative Tumor Profiler Study
Read the Cancer Cell article “Tumor Profiler Study: Integrated multi-omic, functional tumor profiling for clinical decision support” and hear Bernd Bodenmiller discuss his lab’s role in this multi-site collaborative project. He hints at how technologies like IMC could be used to contribute to oncological clinical decision making in the future.
Unless explicitly and expressly stated otherwise, all Fluidigm products are provided for Research Use Only, not for use in diagnostic procedures. For more information see www.fluidigm.com/legal/notices